Gastrointestinal Cancer Articles & Analysis: Older
15 news found
” Headquartered in Cardiff, Wales, and backed by a team of scientists, engineers, and manufacturing technicians, Cellesce technology produces uniform, human-derived cell or organoid lines including off-the-shelf colorectal cancer, gastrointestinal, and breast cancer organoids — with pancreatic and lung organoids under development ...
Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101. ...
The amended license will enable Chimeric to manufacture clinical-grade lentiviral vector for use in its planned phase 1 study of CHM 2101 (CDH17 CAR T) for gastrointestinal cancers. In addition, Chimeric is able to cross-reference regulatory information on file with the US FDA to facilitate filing of an Investigational New Drug (IND) for CHM 2101. ...
More than 50 health conditions are planned for Health Unmuted including diabetes, multiple sclerosis, breast cancer and gastrointestinal conditions. About Mission Based Media Ltd. ...
The results from the myCare-004 clinical study were featured in a poster session as part of the 2022 ASCO Annual Meeting during the Gastrointestinal Cancer – Gastroesophageal Pancreatic and Hepatobiliary Track and available online as Abstract 4064. “This study confirmed that there are many dysregulated signaling pathways responsible for hallmark ...
(Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. ...
Oral Presentation Title: ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC) Abstract Number: 6005 Presenter: Carryn M. Anderson, M.D., University of Iowa Hospitals & Clinics Session Title: Head and Neck Cancer ...
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Phase 1b/2 IMMCO-1 study of tivozanib and atezolizumab in multiple immunologically cold tumors AVEO Oncology (Nasdaq: AVEO), a commercial stage, ...
(Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium ...
Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data ...
ByAlkermes
C2i Genomics, a cancer intelligence company, today announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. ...
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“the Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the first patient was dosed in the KEYNOTE-B79 Phase 1b trial (NCT04991948). ...
EndoClot® SIA is the first starch-derived submucosal injection system cleared in the U.S. market for endoscopic removal of polyps, adenomas, early stage cancers and other gastrointestinal mucosal lesions. Starch based polysaccharide has a long history of clinical applications with an excellent safety profile. ...
Researchers and oncologists took note, not due to the attention-grabbing headlines, but because their focus was to pair the decoded cannabis genome research with sequencing of the DNA of cancer tumors for new research on cannabis and cancer. The news was a celebration of the completion of a key component for those striving to research the affects of using ...
Perma-Fix has applied for patents covering various steps of the process and will incorporate PNNL's technology into its process.Tc-99m is used in the nuclear medicine field for 80-85% of the approximately 25 million diagnostic nuclear medical procedures performed each year, from functional cardiac imaging aiding in the diagnosis of a large number of heart diseases; cancer ...